Clinical HoldZentalis Pharmaceuticals announced that its lead synthetic lethality molecule, WEE1 inhibitor ZN-c3 has been placed on partial clinical hold following the deaths of two patients in one of its monotherapy studies.
Market ChallengesZentalis' entire pipeline is centered around the Zn-c3 molecule, which is now facing significant clinical and market challenges.
Toxicity IssuesThe toxicity issues for ZN-c3 seem to stem from off-targeting of the PLKs, which have led to the need to use intermittent dosing to try to balance the efficacy/toxicity profile.